COVID-19 Serology in New York State Using a Multiplex Microsphere Immunoassay
Hunt, D. T.; Yates, J. L.; Kulas, K. E.; Carson, K.; Lamson, T.; Demarest, V.; Furuya, A.; Howard, K.; Marchewka, M.; Stone, R.; Tucker, H.; Warszycki, C.; Yee, J.; Yang, H. S.; Racine-Brzostek, S.; Zhao, Z.; Ejemel, M.; Li, Q.; Wang, Y.; Fernando, S.; La Carpia, F.; Hod, E. A.; McDonough, K. A.; Lee, W. T.
Show abstract
The emergence of SARS-CoV-2, leading to COVID-19, necessitated the development of new molecular and serological tests. Here, we describe a multiplexed serological assay developed as the global pandemic moved into New York State in the spring of 2020. The original microsphere immunoassay used a target antigen from the SARS-CoV-1 virus responsible for the 2003 SARS outbreak, but evolved to incorporate multiple SARS-CoV-2 protein antigens (nucleocapsid, spike and spike domains, spike and nucleocapsid proteins from seasonal human coronaviruses). Besides being highly versatile due to multiplex capabilities, the assay was highly specific and sensitive and adaptable to measuring both total antibodies and antibody isotypes. While determining the assay performance characteristics, we were able to identify antibody production patterns (e.g., kinetics of isotypes, individual variations) for total antibodies and individual antibody classes. Overall, the results provide insights into the laboratory response to new serology needs, and how the evolution and fine-tuning of a serology assay helped contribute to a better understanding of the antibody response to SARS-CoV-2.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunity 98%
- Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens 97%
- Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays in infected, recovered, and vaccinated groups 97%
Similar papers in this journal
- Rapid and Quantitative Detection of Human Antibodies Against the 2019 Novel Coronavirus SARS CoV2 and its Variants as a Result of Vaccination and Infection 95%
- A highly sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex immunoassay (FMIA) to measure IgG, IgA and IgM class antibodies 95%
- Quantitating SARS-CoV-2 Neutralizing Antibodies from Human Dried Blood Spots 95%
Similar papers in this journal
- Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform 98%
- A novel assessment method for COVID-19 humoral immunity duration using serial measurements in naturally infected and vaccinated subjects 95%
- Seroprevalence of SARS-CoV-2 Infection in Cincinnati Ohio USA from August to December 2020 95%
Similar papers in this journal
- Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 RBD variants with a novel competitive multiplex assay 94%
- Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents 94%
- Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure 93%
Similar papers in this journal
- Highly versatile antibody binding assay for the detection of SARS-CoV-2 infection 98%
- Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination 96%
- Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.